These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27244269)

  • 21. Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients.
    Achour M; Kahla S; Zeghal D; Kochbati L; Mongi M; Zouari F; Oueslati R
    Viral Immunol; 2009 Feb; 22(1):7-16. PubMed ID: 19210223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
    Villa LL
    Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.
    Gersch ED; Gissmann L; Garcea RL
    Antivir Ther; 2012; 17(3):425-34. PubMed ID: 22293302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.
    Gupta SK; Singh A; Srivastava M; Gupta SK; Akhoon BA
    Vaccine; 2009 Dec; 28(1):120-31. PubMed ID: 19799841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
    Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
    J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
    Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
    Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
    Ahmed AI; Bissett SL; Beddows S
    Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
    Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.
    Karanam B; Jagu S; Huh WK; Roden RB
    Immunol Cell Biol; 2009; 87(4):287-99. PubMed ID: 19421199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Polymorphisms of human papillomavirus type 81 L1 gene in patients with cervical lesions in Guangdong].
    Zeng L; Yu SY; Hu ZH; Zhang J
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2210-2. PubMed ID: 19114360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum.
    Kohl TO; Hitzeroth II; Christensen ND; Rybicki EP
    BMC Biotechnol; 2007 Sep; 7():56. PubMed ID: 17850660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Papillomavirus-like particle based vaccines: cervical cancer and beyond.
    Schiller JT; Lowy DR
    Expert Opin Biol Ther; 2001 Jul; 1(4):571-81. PubMed ID: 11727495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPV vaccines to prevent cervical cancer and genital warts: an update.
    Dochez C; Bogers JJ; Verhelst R; Rees H
    Vaccine; 2014 Mar; 32(14):1595-601. PubMed ID: 24606637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression, purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli].
    Yan C; Li S; Wang J; Wei M; Huang B; Zhuang Y; Li Z; Pan H; Zhang J; Xia N
    Wei Sheng Wu Xue Bao; 2009 Nov; 49(11):1527-33. PubMed ID: 20112683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
    Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
    Gene; 2021 May; 782():145533. PubMed ID: 33636291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An effective DNA priming-protein boosting approach for the cervical cancer vaccination.
    Kianmehr Z; Ardestani SK; Soleimanjahi H; Farahmand B; Abdoli A; Khatami M; Akbari K; Fotouhi F
    Pathog Dis; 2015 Mar; 73(2):1-8. PubMed ID: 25722486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Self-Assembling Plant-Derived Vaccines Against Papillomaviruses.
    Noris E
    Methods Mol Biol; 2018; 1776():85-95. PubMed ID: 29869236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.